Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465957 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
A Phase 2 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02465957: Clinical Trial Phase 2 study, sponsored by ImmunityBio.
NCT02465957 is a Phase 2 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465957, a Phase 2 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
Interventions
- BIOLOGICAL aNK (NK-92)
- BIOLOGICAL aNK (NK-92) + N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-03-19 |
| Phase | Phase 2 |
Why NCT02465957 stopped before completion
NCT02465957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which aNK (NK-92) is the first listed.
NCT02465957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465957 about?
NCT02465957 is a clinical study titled "QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)". Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
What is the current status of trial NCT02465957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-09-24. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT02465957?
The interventions under investigation include: aNK (NK-92) (BIOLOGICAL), aNK (NK-92) + N-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465957?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465957's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI